Miller Howard Investments 13F: Cuts JNJ Stake by $23M

Miller Howard Investments cut its stake in Johnson & Johnson (NYSE: JNJ) by 86,267 shares, valued at about $22.8 million, in a filing on October 26, 2026. The fund now holds 317,257 shares of the healthcare company, which is worth approximately $83.99 million.

JNJ Johnson & Johnson

$263.81 ▲ +29.27% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Miller Howard Investments' Johnson & Johnson Position

Miller Howard Investments reduced its holdings in Johnson & Johnson by 86,267 shares, a 21.4% decrease from its previous total of 403,524 shares. This position now accounts for 7.79% of the fund's overall portfolio, ranking it second among its 159 reported positions.

Where Johnson & Johnson Fits in Miller Howard Investments' Portfolio

The cut in Johnson & Johnson shares represents a significant dollar change of about $22.8 million.

Other Institutional Activity in Johnson & Johnson

Several other funds have also adjusted their stakes in Johnson & Johnson recently. Signaturefd grew its holdings by 4,917 shares, bringing its total to 77,490 shares valued at about $20.5 million. Meanwhile, Ag2R la Mondiale Gestion D'Actifs reduced its stake by 13,849 shares, now holding 128,512 shares worth approximately $34.0 million. J. Safra Sarasin Holding also trimmed its position by 42,490 shares, holding a total of 414,478 shares valued at about $103.5 million.

Johnson & Johnson Stock Up 1.0%

As of October 27, 2026, Johnson & Johnson shares traded around $266.35, which is about equal to the closing price of $266.30 on the filing date. The stock is currently above its 50-day moving average of $265.32 and its 200-day moving average of $245.78, but it remains below its 52-week high of $281.07.

Recent Earnings

Johnson & Johnson reported trailing twelve-month revenue of approximately $99.33 billion, with an earnings per share (EPS) of $6.59. The next earnings report is scheduled for January 26, 2027.

Dividend

Johnson & Johnson pays an annual dividend rate of $5.36 per share, yielding about 2.01%.

Insider Buying and Selling at Johnson & Johnson

Several insiders have sold shares of Johnson & Johnson recently. On August 6, 2026, Officer Elizabeth Forminard sold 15,918 shares valued at about $4.09 million. CEO Joaquin Duato sold 123,291 shares on August 13, 2026, worth approximately $32.20 million. Additionally, Officer Jennifer L. Taubert sold 15,000 shares on August 17, 2026, valued at around $3.95 million, and Officer Timothy Schmid sold 33,597 shares on September 2, 2026, worth about $9.23 million.

Analysts Set New Price Targets

On October 14, 2026, Leerink Partners maintained its rating of "Outperform" on Johnson & Johnson with a price target of $272. Wells Fargo also maintained its "Overweight" rating with a target of $275. RBC Capital kept its "Outperform" rating with a target of $280, and Morgan Stanley maintained an "Overweight" rating with a target of $292.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells a wide array of products, including pharmaceuticals and medical devices. This recent reduction in stake by Miller Howard Investments may reflect broader market trends or shifts in investment strategy.

Bottom Line

Investors should keep an eye on Johnson & Johnson's upcoming earnings report on January 26, 2027, as well as any further filings from institutional investors like Miller Howard Investments. The stock remains a significant part of Miller Howard's portfolio, but this reduction may signal changing perspectives on its future performance.